• D E Lekka, J Brucknerova, A Salingova, C Sebova, M Ostrozlikova, J Ziburova, M Nemcovic, S Sestak, J Bellova, Z Pakanova, B Sivakova, M Skoknova, V Bzduch, J Mucha, P Barath, and I Brucknerova.
• Bratisl Med J. 2021 Jan 1; 122 (3): 190-195.

AimCongenital disorders of glycosylation (CDG) belong to an expanding group of rare genetic metabolic disorders caused by defects in the complex chemical enzymatic process of glycosylation. The study is aimed at presenting a case report of a premature dysmorphic newborn, clinical presentation of the condition, the way it was diagnosed and treated, as well as its comparison with the known cases.ResultsThe result of glycan analysis supports the assumption of a supposed glycosylation disorder and also specifies a specific subtype: CDG-1, subtype ALG12-CDG (Ig).ConclusionCDG have an extremely wide clinical spectrum and should be considered in any child with unexplained developmental delay, failure to thrive, seizures, and abnormalities in liver enzymes, coagulation and immunologic factors. The treatment of most forms of CDG depends upon numerous factors such as specific symptoms present, severity of the disorder, age and overall health of the patients and tolerance to certain medications or procedures. For these reasons, the treatment is specific for every individual. It is based on the symptoms and requires a coordination of efforts of a team of specialists (Tab. 4, Fig. 3, Ref. 19).

13 keywords...

hide…